53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.
6 citations
,
November 2022 in “BMC Urology” In this study, researchers found that the microRNA miR-1199-5p may reduce the expression of SRD5A2 in benign prostatic hyperplasia tissues, potentially contributing to the failure of 5-α reductase inhibitor therapy in some patients.
1 citations
,
February 2023 in “Russian Journal of Bioorganic Chemistry” In an animal study, researchers observed that a newly synthesized deoxycholic acid derivative showed similar prostate protection effects to finasteride in Wistar rats while being less toxic.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” This study identified six molecules from herbal extracts that effectively bind to 5-alpha reductase (5-AR), with Jomogenin showing high binding stability when encapsulated in lipid nanoparticles, suggesting their potential for further experimental analysis to aid hair follicle growth.
March 2010 in “The Journal of Urology” This study demonstrated that methylation of the 5-alpha reductase type 2 (5-AR2) promoter is linked to reduced expression of the 5-AR2 protein, possibly explaining resistance to Finasteride in some BPH patients.